# US 2010/0144722 A1 · Novel heterocyclic compounds as gata modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144722 A1
- Document ID: US20100144722A1
- Status: Published application
- Kind: A1
- Application number: 12/553,623
- Filed: 2009-09-03
- Published: 2010-06-10
- Earliest claimed: 2008-09-03
- Assignees: Dr. Reddy's Laboratories, Inc.
- Inventors: Christopher W. Alexander; Dibyendu De; Ish Kumar Khanna; Sivaram Pillarisetti
- Web page: https://patentgrep.com/patent/US20100144722A1

## CPC

- C07D 239/48: Two nitrogen atoms
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel heterocyclic compounds, sstereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided. Additionally, methods of forming novel heterocyclic compounds, stereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided.

## Claims

### Claim 1

A compound of formula (I),
stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (I) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (I); wherein,
X, Y and Z are each independently selected from N or CRb, wherein Rb is selected from hydrogen, halogen or alkyl; with a proviso that when X and Y are each independently N, Z is —CRb and when Y and Z are each independently N, X is —CRb;
A is a 3 to 7 membered cycloalkyl ring;
B is an optionally substituted group selected from alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or —NR2R3, wherein one or more optional substituents on B are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, alkoxy, cycloalkyl, —CO-alkyl, —COORc, —CONRdRe, —(CH2)nSO2Rf, —(CH2)nSO2NRcRd, aryl, heteroaryl or heterocyclyl;
R1 is selected from hydrogen or alkyl;
R2 and R3 are each independently selected from hydrogen, —(CH2)n-hydroxy, —(CH2)n-halogen, and an optionally substituted group selected from alkyl, —(CH2)n-cycloalkyl, —(CH2)n-heterocyclyl, —(CH2)n-aryl or —(CH2)n-heteroaryl, wherein one or more optional substituents on R2 and R3 are each independently selected from halogen, cyano, hydroxy, alkyl, cycloalkyl, alkoxy, —CO-alkyl, —COORc, —CONRdRe, —(CH2)nSO2Rf, —(CH2)nSO2NRcRd, aryl, heteroaryl or heterocyclyl; or
R2 and R3 optionally combine with the nitrogen atom, to which they are attached, to form an optionally substituted 5- to 6-membered heterocyclic ring optionally having 1 to 3 additional hetero atoms or groups selected from nitrogen, oxygen, sulfur, SO2 or CO, wherein one or more optional substituents on the heterocyclic ring are selected from halogen, hydroxy, alkoxy, alkyl, cycloalkyl or —CO-alkyl;
R4 is hydrogen or an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R4 are selected from halogen, hydroxy, cyano, alkyl, —(CH2)n—OH, cycloalkyl, alkoxy or —CO-alkyl;
Ra is selected from cyano, —(CH2)n—OH, —(CH2)n-alkoxy, alkyl, aryl, —NH-aryl, heteroaryl, —(CH2)nCO-alkyl, —(CH2)nCOORc, —(CH2)nCONRdRe, —(CH2)nSO2Rf, or —(CH2)nSO2NRcRd;
Rc is selected from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl;
Rd and Re are each independently selected from hydrogen or an optionally substituted group selected from alkyl, cycloalkyl, alkoxy, aryl, heteroaryl or heterocyclyl, wherein one or more optional substituents on Rd and Re are each independently selected from halogen, hydroxy or alkyl;
Rf is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and
n is an integer from 0 to 2.

### Claim 2 (depends on 1)

The compound as claimed in claim 1, having the formula (II)
stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (II) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (II)

### Claim 3 (depends on 1)

The compound as claimed in claim 1, having the formula (III)
stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (III) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (III).

### Claim 4 (depends on 3)

The compound as claimed in claim 3, wherein
A is selected from cyclopropyl, cyclobutyl or cyclopentyl;
R1 is hydrogen;
R2 is selected from hydrogen or —(CH2)n-cycloalkyl;
R3 is selected from hydrogen, —(CH2)n-hydroxy, —(CH2)n-halogen, and an optionally substituted group selected from alkyl, —(CH2)n-cycloalkyl, —(CH2)n-heterocyclyl, —(CH2)n-aryl or —(CH2)n-heteroaryl; wherein one or more optional substituents on R2 and R3 are each independently selected from halogen, cyano, hydroxy, alkyl, cycloalkyl, alkoxy, —CO-alkyl, —COORc, —CONRdRe, —(CH2)nSO2Rf, —(CH2)nSO2NRcRd, aryl, heteroaryl or heterocyclyl;
R4 is an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R4 are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy or —CO-alkyl;
Ra is selected from cyano, alkyl, —(CH2)n—OH, —(CH2)n-alkoxy, —CO-alkyl, heteroaryl, —(CH2)nCOORc, —(CH2)nCONRdRe, —(CH2)nSO2Rf or —(CH2)nSO2NRcRd;
Rb is selected from hydrogen or alkyl;
Rc is selected from hydrogen or alkyl;
Rd and Re are each independently selected from hydrogen, alkyl, alkoxy or aryl, which is optionally substituted with halogen;
Rf is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and
n is an integer from 0 to 2.

### Claim 5 (depends on 4)

The compound as claimed in claim 4, wherein
R3 is selected from hydrogen, alkyl, —(CH2)n-cycloalkyl, and optionally substituted groups selected from —(CH2)n—OH, —(CH2)n-heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, wherein the optional substituents on R3 are selected from halogen, —CH2—OH, alkyl, aryl, —(CH2)nSO2NRcRd or —(CH2)nSO2Rf;
R4 is selected from an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R4 are selected from halogen, alkyl or alkoxy;
Ra is selected from cyano, alkyl, —(CH2)n—OH, —(CH2)n-alkoxy, —CO-alkyl, heteroaryl, —COORc, —CONRdRe, —(CH2)nSO2Rf or —(CH2)nSO2NRcRd;
Rc is selected from hydrogen or alkyl, and
Rd and Re are each independently selected from hydrogen, alkyl, alkoxy or aryl, which is optionally substituted with halogen.

### Claim 6 (depends on 3)

The compound as claimed in claim 3, wherein
R2 and R3 combine with the nitrogen atom, to which they are attached, to form an optionally substituted 5- to 6-membered heterocyclic ring optionally having 1 to 3 additional hetero atoms or groups selected from nitrogen, oxygen, sulfur, SO2 or CO, wherein one or more optional substituents on the heterocyclic ring fowled may be selected from halogen, hydroxyl, alkoxy, alkyl, cycloalkyl or —CO-alkyl;
R4 is an optionally substituted group selected from cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R4 are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy or —CO-alkyl;
Ra is selected from cyano, alkyl, —(CH2)n—OH, —(CH2)n-alkoxy, —CO-alkyl, heteroaryl, —COORc, —CONRdRe, —(CH2)nSO2Rf or —(CH2)nSO2NRcRd;
Rc is selected from hydrogen or alkyl;
Rd and Re are each independently selected from hydrogen, alkyl or alkoxy;
Rf is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and
n is an integer from 0 to 2.

### Claim 7 (depends on 6)

The compound as claimed in claim 6, wherein
R2 and R3 combine with the nitrogen atom, to which they are attached, to form an optionally substituted morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, dioxo-thiomorpholinyl, wherein one or more optional substituents on the heterocyclic ring formed may be selected from halogen, hydroxy, alkoxy, alkyl or —CO-alkyl;
R4 is an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R4 are selected from halogen, alkyl or alkoxy;
Ra is selected from —COORc or —CONRdRe;
Rc is selected from hydrogen or alkyl; and
Rd and Re are independently selected from hydrogen, alkyl, alkoxy or aryl, which is optionally substituted with halogen.

### Claim 8 (depends on 1)

The compound as claimed in claim 1, having the formula (IV),
stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (IV) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (IV).

### Claim 9 (depends on 8)

The compound as claimed in claim 8, wherein
R1 is hydrogen;
A is selected from cyclopropyl, cyclobutyl or cyclopentyl;
B is an optionally substituted group selected from alkyl, cycloalkyl, aryl, heteroaryl or —NR2R3, wherein one or more optional substituents on B are selected from halogen, hydroxy, alkyl, haloalkyl, alkoxy, —CO-alkyl, —(CH2)nSO2Rf or —(CH2)nSO2NRcRd;
R3 is selected from hydrogen, —(CH2)n—OH, —(CH2)n-cycloalkyl, an optionally substituted groups selected from alkyl, —(CH2)n-heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, wherein one or more optional substituents on R3 are selected from halogen, —CH2—OH, alkyl, aryl, —(CH2)nSO2NRcRd or —(CH2)nSO2Rf;
R4 is an optionally substituted group selected from alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R4 are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy or —CO-alkyl;
Ra is selected from cyano, alkyl, —(CH2)n—OH, —(CH2)n-alkoxy, —CO-alkyl, heteroaryl, —COORc, —CONRdRe, —(CH2)nSO2Rf or —(CH2)—SO2NRcRd;
Rc is hydrogen;
Rd and Re are each independently selected from hydrogen, alkyl, alkoxy or aryl, which is optionally substituted with halogen;
Rf is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and
n is an integer from 0 to 2.

### Claim 10 (depends on 8)

The compound as claimed in claim 8, wherein
stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (V) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (V); wherein
R2 and R3 combine with the nitrogen atom, to which they are attached, to form an optionally substituted 5- to 6-membered cyclic ring optionally having 1 to 3 additional hetero atoms or groups selected from nitrogen, oxygen, sulfur, SO2 or CO; wherein one or more optional substituents on the heterocyclic ring formed may be selected from halogen, hydroxy, alkoxy, alkyl, cycloalkyl or —CO-alkyl;
R4 is an optionally substituted group selected from cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R4 are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy or —CO-alkyl;
Ra is selected from —(CH2)n—OH, —(CH2)nCOORc, —(CH2)nCONRdRe, —(CH2)nSO2Rf or —(CH2)nSO2NRcRd;
Rc is hydrogen;
Rd and Re are each independently selected from hydrogen, alkyl or alkoxy;
Rf is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and
n in an integer from 0 to 2.

### Claim 11

A composition comprising one or more compounds selected from:
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopropane carboxylic acid,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopentane carboxylic acid,
1-[4-(4-tert-Butyl-6-tert-butylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-(4-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-6-phenyl-pyrimidin-2-ylamino}-phenyl)-cyclobutanecarboxylic acid methyl ester,
1-[4-(4-tert-Butylamino-5-fluoro-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-{4-[4-(Bis-cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid methyl ester,
1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclopentanecarboxylic acid,
1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Methylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-{4-[4-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(Bicyclo[2.2.1]hept-2-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Fluoro-phenyl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Fluoro-phenyl)-6-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Cyclobutylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-{4-[4-(1,1-Dimethyl-propylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Fluoro-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Methanesulfonyl-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(2-Hydroxy-1-phenyl-ethyl amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Amino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-{4-[4-(5-Methyl-isoxazol-3-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Cyclopentyl-6-cyclopentylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-[4-(4-tert-Butylamino-6-cyclopentyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-pyrrolidin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Hydroxy-piperidin-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{3-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-5-methyl-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-piperazin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Acetyl-piperazin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(6-Methoxy-pyridin-3-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4,4-Difluoro-piperidin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-tert-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-Cyclopentylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarbonitrile,
Sodium 1-[4-(4-tert-butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylate,
{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutyl}-methanol,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid ethylamide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid dimethylamide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid tert-butylamide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid amide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid methoxy-methyl-amide,
1-{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutyl}-ethanone,
N4-tert-Butyl-N2-[4-(1-oxazol-2-yl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid (4-fluoro-phenyl)-amide,
(1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-methanol,
N4-tert-Butyl-N2-[4-(1-methoxymethyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
N4-tert-Butyl-N2-[4-(1-methyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-yl]-[4-(1-methanesulfonylmethyl-cyclobutyl)-phenyl]-amine,
1-[4-(2-tert-Butylamino-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-{4-[2-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(6-tert-Butylamino-2-phenyl-pyrimidin-4-ylamino)-phenyl)-cyclobutane carboxylic acid,
1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-methyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(4-Fluoro-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(4-Acetyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(6-Methoxy-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(4-Methanesulfonyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(6-Methyl-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-}4-[2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-morpholin-4-yl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(2-Morpholin-4-yl-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-[4-(4-Isopropoxy-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

### Claim 12 (depends on 11)

The compound as claimed in claim 11, wherein the compound is:
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-yl-amino)-phenyl]-cyclopropanecarboxylic acid,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopentanecarboxylic acid,
1-[4-(4-tert-Butyl-6-tert-butylamino-pyrimidin-2-ylamino]-phenyl]-cyclobutanecarboxylic acid,
1-(4-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-6-phenyl-pyrimidin-2-ylamino}-phenyl)-cyclobutanecarboxylic acid methyl ester,
1-[4-(4-tert-Butylamino-5-fluoro-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-{4-[4-(bis-Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid methyl ester,
1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclopentane-carboxylic acid,
1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutane-carboxylic acid,
1-[4-(4-Methylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-{4-[4-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutane carboxylic acid,
1-{4-[4-(Bicyclo[2.2.1]hept-2-ylamino)-6-phenyl-pyrimidin-2-ylamino}-phenyl}-cyclobutane carboxylic acid,
1-[4-(4-Cyclobutylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane-carboxylic acid,
1-{4-[4-(1,1-Dimethyl-propylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Fluoro-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Methanesulfonyl-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
(1-{4-[4-Phenyl-6-((R)-1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-acetic acid,
(1-{4-[4-Phenyl-6-((S)-1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-acetic acid,
1-{4-[4-((S)-2-Hydroxy-1-phenyl-ethylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Amino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane-carboxylic acid,
1-{4-[4-(5-Methyl-isoxazol-3-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Cyclopentyl-6-cyclopentylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-[4-(4-tert-Butylamino-6-cyclopentyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-{4-[4-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutane carboxylic acid,
1-{4-[4-tert-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-Cyclopentylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-yl-amino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarbonitrile,
Sodium1-[4-(4-tert-butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylate,
{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylmethyl)-phenyl]-cyclobutyl}-methanol,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid ethylamide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid dimethylamide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid tert-butylamide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid methoxy-methyl-amide,
1-{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutyl}-ethanone,
N4-tert-Butyl-N2-[4-(1-oxazol-2-yl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid (4-fluoro-phenyl)-amide,
N4-tert-Butyl-N2-[4-(1-methoxymethyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
N4-tert-Butyl-N2-[4-(1-methyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine;
stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

### Claim 13 (depends on 11)

The compound as claimed in claim 11, wherein the compound is
1-{4-[4-(4-fluoro-phenyl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutane-carboxylic acid,
1-{4-[4-(4-fluoro-phenyl)-6-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutane-carboxylic acid,
1-{4-[4-(1-methyl-1H-pyrazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(1-methyl-1H-pyrazol-4-yl)-6-pyrrolidin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-hydroxy-piperidin-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(3,5-dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{3-[4-(3,5-dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(3,5-dimethyl-isoxazol-4-yl)-6-piperazin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-acetyl-piperazin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(6-methoxy-pyridin-3-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4,4-difluoro-piperidin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
(1-{4-[4-(3,5-dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-methanol,
[4-(3,5-dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-yl]-[4-(1-methanesulfonyl methyl-cyclobutyl)-phenyl]-amine,
stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

### Claim 14 (depends on 11)

The compound as claimed in claim 11, wherein the compound is
1-[4-(2-tert-butylamino-6-phenyl-pyrimidin-4-ylamino)-phenyl}-cyclobutane-carboxylic acid,
1-{4-[2-(tert-butyl-methyl-amino)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutane carboxylic acid,
1-[4-(6-tert-butylamino-2-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-{4-[6-(3,5-dimethyl-isoxazol-4-yl)-2-methyl-pyrimidin-4-ylamino]-phenyl}-cyclobutane carboxylic acid,
1-{4-[2-(4-fluoro-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(4-acetyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[6-3,5-dimethyl-isoxazol-4-yl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(6-methoxy-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutane carboxylic acid,
1-{4-[2-(4-methanesulfonyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutane carboxylic acid,
1-{4-[2-(6-methyl-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[6-(3,5-dimethyl-isoxazol-4-yl)-2-morpholin-4-yl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(2-morpholin-4-yl-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutanecarboxylic acid,
stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to claim 1.

### Claim 16 (depends on 1)

A compound as claimed in claim 1, wherein the compound is a GATA modulator.

### Claim 17

A method for the treatment of atherosclerosis and/or diabetes in a subject, which comprises administering to the subject a therapeutically effective amount of a compound comprising:
stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (I) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (I); wherein,
X, Y and Z are each independently selected from N or CRb, wherein Rb is selected from hydrogen, halogen or alkyl; with a proviso that when X and Y are each independently N, Z is —CRb and when Y and Z are each independently N, X is —CRb;
A is a 3 to 7 membered cycloalkyl ring;
B is an optionally substituted group selected from alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or —NR2R3, wherein one or more optional substituents on B are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, alkoxy, cycloalkyl, —CO-alkyl, —COORc, —CONRdRe, —(CH2)nSO2Rf, —(CH2)nSO2NRcRd, aryl, heteroaryl or heterocyclyl;
R1 is selected from hydrogen or alkyl;
R2 and R3 are each independently selected from hydrogen, —(CH2)n-hydroxy, —(CH2)n-halogen, and an optionally substituted group selected from alkyl, —(CH2)n-cycloalkyl, —(CH2)n-heterocyclyl, —(CH2)n-aryl or —(CH2)n-heteroaryl, wherein one or more optional substituents on R2 and R3 are each independently selected from halogen, cyano, hydroxy, alkyl, cycloalkyl, alkoxy, —CO-alkyl, —COORc, —CONRdRe, —(CH2)nSO2Rf, —(CH2)nSO2NRcRd, aryl, heteroaryl or heterocyclyl; or
R2 and R3 optionally combine with the nitrogen atom, to which they are attached, to form an optionally substituted 5- to 6-membered heterocyclic ring optionally having 1 to 3 additional hetero atoms or groups selected from nitrogen, oxygen, sulfur, SO2 or CO, wherein one or more optional substituents on the heterocyclic ring are selected from halogen, hydroxy, alkoxy, alkyl, cycloalkyl, or —CO-alkyl;
R4 is hydrogen or an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R4 are selected from halogen, hydroxy, cyano, alkyl, —(CH2)n—OH, cycloalkyl, alkoxy or —CO-alkyl;
Ra is selected from cyano, —(CH2)n—OH, —(CH2)n-alkoxy, alkyl, aryl, —NH-aryl, heteroaryl, —(CH2)nCO-alkyl, —(CH2)nCOORc, —(CH2)nCONRdRe, —(CH2)nSO2Rf, or —(CH2)nSO2NRcRd;
Rc is selected from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl;
Rd and Re are each independently selected from hydrogen or an optionally substituted group selected from alkyl, cycloalkyl, alkoxy, aryl, heteroaryl or heterocyclyl, wherein one or more optional substituents on Rd and Re are each independently selected from halogen, hydroxy or alkyl;
Rf is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and
n is an integer from 0 to 2.

### Claim 18 (depends on 17)

The method as claimed in claim 17, comprising treating a subject having diabetes.

### Claim 19 (depends on 17)

The method as claimed in claim 17, comprising treating a subject having atherosclerosis.

### Claim 20

A method for the treatment of atherosclerosis and/or diabetes in a subject, which comprises administering to the subject a therapeutically effective amount of at least one compound selected from one or more of:
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclopropane carboxylic acid,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopentane carboxylic acid,
1-[4-(4-tert-Butyl-6-tert-butylamino-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
1-(4-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-6-phenyl-pyrimidin-2-ylamino}-phenyl)-cyclobutanecarboxylic acid methyl ester,
1-[4-(4-tert-Butylamino-5-fluoro-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-{4-[4-(Bis-cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid methyl ester,
1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclopentanecarboxylic acid,
1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Methylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
1-{4-[4-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(Bicyclo[2.2.1]hept-2-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Fluoro-phenyl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Fluoro-phenyl)-6-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Cyclobutylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
1-{4-[4-(1,1-Dimethyl-propylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Fluoro-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Methanesulfonyl-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-8 4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(2-Hydroxy-1-phenyl-ethylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Amino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-{4-[4-(5-Methyl-isoxazol-3-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Cyclopentyl-6-cyclopentylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
1-[4-(4-tert-Butylamino-6-cyclopentyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-pyrrolidin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Hydroxy-piperidin-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{3-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-5-methyl-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-piperazin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4-Acetyl-piperazin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(6-Methoxy-pyridin-3-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-(4,4-Difluoro-piperidin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-tert-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[4-Cyclopentylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarbonitrile,
Sodium 1-[4-(4-tert-butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylate,
{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutyl}-methanol,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid ethylamide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid dimethylamide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid tert-butylamide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid amide,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid methoxy-methyl-amide,
1-{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutyl}-ethanone,
N4-tert-Butyl-N2-[4-(1-oxazol-2-yl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid (4-fluoro-phenyl)-amide,
(1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-methanol,
N4-tert-Butyl-N2-[4-(1-methoxymethyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
N4-tert-Butyl-N2-[4-(1-methyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-yl]-[4-(1-methanesulfonylmethyl-cyclobutyl)-phenyl]-amine,
1-[4-(2-tert-Butylamino-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-{4-[2-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(6-tert-Butylamino-2-phenyl-pyrimidin-4-ylamino)-phenyl}-cyclobutane carboxylic acid,
1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-methyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(4-Fluoro-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-]2-(4-Acetyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(6-Methoxy-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(4-Methanesulfonyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(6-Methyl-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-morpholin-4-yl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
1-[4-(2-Morpholin-4-yl-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,
1-[4-(4-Isopropoxy-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

### Claim 21 (depends on 20)

The method as claimed in claim 20, comprising treating a subject having diabetes.

### Claim 22 (depends on 20)

The method as claimed in claim 20, comprising treating a subject having atherosclerosis.